TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02542267

Intervention type: DEVICE
Group type: OTHER
Intervention: Gore VIABAHN Endoprosthesis
Study: NCT04351139

Intervention type: OTHER
Intervention: modification of the planned therapeutic management
Description: to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers

Intervention type: OTHER
Intervention: modification of the planned therapeutic management
Description: to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers
Study: NCT02631707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: The intervention diet is higher in protein than the control diet.
Study: NCT01799876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Cell

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard microfracture arthroscopic surgery
Study: NCT01054833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needleless mid-urethral sling
Description: The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
Study: NCT02909621

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FLEXOFYTOL®
Description: The product FLEXOFYTOL® is bio-optimized curcumin.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FLEXOFYTOL®
Description: The product FLEXOFYTOL® is bio-optimized curcumin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study: NCT04278807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia - Nerve Blocks
Description: Regional Anesthesia and ultrasound-guided nerve blocks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia - Nerve Blocks
Description: Regional Anesthesia and ultrasound-guided nerve blocks
Study: NCT03176316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone is an opioid antagonist (i.e., a medication used to reverse or reduce the effects of opioids)
Study: NCT00531960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg, PO, daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg, IV, Day 1 of Cycles 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV, Day 1 of Cycles 1 through 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard platinum-based chemotherapy
Description: At the discretion of the investigator
Study: NCT03486392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 1
Description: Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 2
Description: Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 3
Description: Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo SC once-weekly until Week 26.
Study: NCT03803527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal String Test
Description: An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
Study: NCT03034603

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri-jelly with PEITC
Description: Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutri-jelly
Description: Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
Study: NCT04371367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avdoralimab
Description: intravenous administration of avdoralimab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous administration of placebo
Study: NCT00679458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine and low-dose naloxone
Description: each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine alone
Description: each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
Study: NCT03544112

Intervention type: BEHAVIORAL
Intervention: Employ a multifaceted approach to facilitate clinical protocol implementation
Description: Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.

Intervention type: BEHAVIORAL
Intervention: Employ a multifaceted approach to facilitate clinical protocol implementation
Description: Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.

Intervention type: BEHAVIORAL
Intervention: Employ a multifaceted approach to facilitate clinical protocol implementation
Description: Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.

Intervention type: DRUG
Intervention: Initiate BUP (SL-BUP or XR-BUP) in the ED
Description: The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
Study: NCT03822481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Construal Diary
Description: A Mindful Eating Intervention
Study: NCT04325477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nolix Device
Description: The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
Study: NCT01433250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: (10mg/kg i.v.).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: (10mg/kg i.v.).
Study: NCT04083625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbetocin 100 mcg
Description: a 10 cm syringe containing 100 mcg carbetocin just before skin incision of myomectomy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
Study: NCT03632954

Intervention type: DEVICE
Intervention: ACell Arm
Description: Cytal® Wound Matrix and/or MicroMatrix®
Study: NCT03543072

Intervention type: DRUG
Intervention: Bisphosphonates
Description: a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
Study: NCT02338570

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
Study: NCT02747472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP-A
Description: GIP receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP-A
Description: GIP receptor antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP(1-42)
Description: GIP receptor agonist
Study: NCT04709887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound treatment
Description: According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound treatment
Description: According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound treatment
Description: According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.
Study: NCT02747472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP(1-42)
Description: GIP receptor agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT01937429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with blue Indigo Carmin®
Study: NCT03982550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periodized Resistance Training
Description: Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
Study: NCT01712347

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab will be administered as per approved label.
Study: NCT01937429

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy with insufflation of air
Study: NCT02437110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.
Study: NCT04709887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound treatment
Description: According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vascular intervention surgery
Description: Segmented distal angiography under the guidance of digital subtraction angiography (DSA) were perform after local anesthesia. The superficial artery is expanded by a 3-4 mm balloon.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vascular intervention surgery
Description: Segmented distal angiography under the guidance of digital subtraction angiography (DSA) were perform after local anesthesia. The superficial artery is expanded by a 3-4 mm balloon.
Study: NCT02587962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Birinapant intravenous (IV) on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
Study: NCT02601482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW-60
Study: NCT01700309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young and Active
Description: The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
Study: NCT02172534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide medium
Study: NCT01712347

Intervention type: DRUG
Intervention: Chemotherapy
Description: The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
Study: NCT00080847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT02172534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide high

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01037894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: In-patient physiotherapy, occupational therapy and speech therapy.
Study: NCT02956590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Statin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01870323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Behavioral Group
Description: Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
Study: NCT02601482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW-45
Study: NCT04921462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septoplasty surgery
Description: septoplasty procedures were performed by a single surgeon using the same technique among all patients. The procedures were conducted under general anesthesia according to the standard preoperative care used in our institution.
Study: NCT01870323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMART Informational Group
Description: Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
Study: NCT04525885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg twice daily (BID)
Description: Gefapixant 45 mg tablet to be administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 15 mg BID
Description: Gefapixant 15 mg tablet to be administered orally BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg BID
Description: Gefapixant 45 mg tablet to be administered orally BID
Study: NCT04120311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Episcleral Dexamethasone
Description: Sustained Release Episcleral Dexamethasone
Study: NCT01054547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
Study: NCT05893953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediately feedback device
Description: Sitting in a standard chair with immediate feedback device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unstable chair
Description: sitting in an unstable chair

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard chair
Description: Sitting in a standard chair
Study: NCT03853824

Intervention type: OTHER
Group type: OTHER
Intervention: Increased postoperative surveillance
Description: Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual postoperative care
Description: Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
Study: NCT00877123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral vitamin D 100,000 IU
Description: Oral vitamin D 100,000 IU once a month for three consecutive months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar placebo once a month for three consecutive months